Investigational drug · Phase 2
per day for 28 days
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bronchial Asthma.
Phase 2Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7,332
Any phase or sponsor naming "per day for 28 days"
First trial start
2025
Feb 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "per day for 28 days", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bronchial Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "per day for 28 days" as an intervention, largest first.
Sinovac Research and Development Co., Ltd.Industry
NCT04911790 · 131,650 participants · Start Jun 5, 2021 · Primary completion Jan 2, 2023
Drug: Experimental Group · For: COVID-19
Sites: Dali, China
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and AdolescentsCompleted
Sinovac Life Sciences Co., Ltd.Industry
NCT04992208 · 31,041 participants · Start Jul 24, 2021 · Primary completion Mar 24, 2023
Drug: Experimental Group · For: COVID-19
Sites: Dali, China
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)Pivotal-lookingStatus unknown
Shenzhen Kangtai Biological Products Co., LTDIndustry
NCT04852705 · 28,000 participants (planned) · Start May 2021 · Primary completion Nov 2021
Drug: SARS-CoV-2 Vaccine (Vero Cells), Inactivated; Placebo · For: COVID-19
- Delivery and Implementation of a Randomised Crossover Trial on ThrombosisPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06937372 · 21,194 participants (planned) · Start Jul 1, 2026 · Primary completion Oct 31, 2027
Drug: Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.; Low molecular weight heparin (LMWH) · For: Hip Fractures; Venous Thromboembolism (VTE)
Sites: London, United Kingdom
- Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRCPivotal-lookingStatus unknown
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT04152486 · 20,426 participants · Start Nov 14, 2019 · Primary completion Jan 31, 2022
Drug: Ad26.ZEBOV, MVA-BN-Filo vaccine · For: Ebola Virus Disease
Sites: Kinshasa, Democratic Republic of the Congo
- Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and EffectivenessPivotal-lookingRecruiting
Insud PharmaIndustry
NCT06282315 · 20,000 participants (planned) · Start Sep 1, 2025 · Primary completion Apr 2026
Drug: Pre-screening Phase; Screenig Phase and 6 more · For: Soil-Transmitted Helminths
Sites: Accra, Ghana; Nairobi, Kenya
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
Valneva Austria GmbHIndustry
NCT01335412 · 20,000 participants · Start Mar 2011 · Primary completion Jun 2013
Drug: Japanese Encephalitis Virus vaccine, inactivated, adsorbed · For: Japanese Encephalitis
Sites: Alexandria, Virginia
- APEX-STROKE Adaptive Platform Trial for StrokePivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07784569 · 20,000 participants (planned) · Start Sep 1, 2026 · Primary completion Jun 30, 2029
Drug: Early Angong Niuhuang Pill Treatment; Yiqi Huayu Jiedu Mixture · For: Stroke
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Bronchial Asthma
- PA9159 Metered-DosePhase 22 trials
Anhui Palo Alto Pharmaceuticals, Inc. · Bronchial Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.